Want to see TRAW full AI Analyst Report?
TRAW Stock Chart & Stats
$0.49
-$0.03(-6.13%)
At close: 4:00 PM EDT
$0.49
-$0.03(-6.13%)
Day’s Range― - ―
52-Week Range$0.43 - $3.27
Previous CloseN/A
Volume182.49K
Average Volume (3M)206.36K
Market Cap
$6.85M
Enterprise Value$16.35
Total Cash (Recent Filing)$3.13M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.37
Next Earnings
Aug 06, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.98
Shares Outstanding15,228,328
10 Day Avg. Volume403,079
30 Day Avg. Volume206,356
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-14.78
Price to Sales (P/S)3.33
P/FCF Ratio-0.45
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$1.00Price Target Upside104.08% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-1.58
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Capital StructureHaving no debt materially reduces near-term solvency and refinancing risk for a clinical-stage biotech that relies on intermittent capital raises. Long-term, a debt-free capital structure preserves operational flexibility to prioritize R&D spend and negotiate non-dilutive funding without fixed interest burdens.
Broad-spectrum Antiviral Portfolio & PartnershipsTraws' focus on broad-spectrum antivirals and active partnerships with public health agencies builds durable strategic differentiation in pandemic preparedness markets. Local manufacturing plans and regulatory collaboration in Africa support sustained access, potential stockpiling contracts, and longer-term commercial channels beyond single-drug outcomes.
Established Access To Equity FinancingConfirmed PIPE proceeds and an active ATM/shelf program provide repeatable access to capital to fund clinical programs. For a loss-making biotech, durable lines of equity financing extend runway to achieve clinical inflection points, reducing the immediate existential funding risk while enabling milestone-driven development.
Bears Say
Negative EquityNegative shareholders' equity signals cumulative operating losses or write-downs that have eroded the capital base. This structural weakness limits financial flexibility, constrains ability to borrow non-dilutive capital, can complicate grant/partnership negotiations, and raises the probability of future dilutive financings.
Consistent Negative Operating Cash FlowPersistent operating cash burn without positive free cash flow forces reliance on external funding to sustain R&D and trials. Over multiple periods this reduces strategic optionality, increases dilution risk, and creates execution risk if financing windows close before clinical milestones are reached.
Regulatory And Clinical Execution SetbacksDeferral of the Phase 2a influenza challenge trial following a negative MHRA review (and concurrent U.S. IND clinical hold referenced elsewhere in filings) lengthens timelines, raises incremental preclinical/toxicology costs, and increases the probability that key commercial milestones slip or require additional capital to resolve.
Traws Pharma News
TRAW FAQ
What was Traws Pharma’s price range in the past 12 months?
Traws Pharma lowest stock price was $0.43 and its highest was $3.27 in the past 12 months.
What is Traws Pharma’s market cap?
Traws Pharma’s market cap is $6.85M.
When is Traws Pharma’s upcoming earnings report date?
Traws Pharma’s upcoming earnings report date is Aug 06, 2026 which is in 3 days.
How were Traws Pharma’s earnings last quarter?
Traws Pharma released its earnings results on May 15, 2026. The company reported -$0.53 earnings per share for the quarter, beating the consensus estimate of -$0.56 by $0.03.
Is Traws Pharma overvalued?
According to Wall Street analysts Traws Pharma’s price is currently Undervalued.
Does Traws Pharma pay dividends?
Traws Pharma does not currently pay dividends.
What is Traws Pharma’s EPS estimate?
Traws Pharma’s EPS estimate is -0.34.
How many shares outstanding does Traws Pharma have?
Traws Pharma has 15,228,328 shares outstanding.
What happened to Traws Pharma’s price movement after its last earnings report?
Traws Pharma reported an EPS of -$0.53 in its last earnings report, beating expectations of -$0.56. Following the earnings report the stock price went up 15.337%.
Which hedge fund is a major shareholder of Traws Pharma?
Currently, no hedge funds are holding shares in TRAW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Traws Pharma
Traws Pharma, Inc. (TRAW) is a clinical-stage biopharmaceutical company focused on developing antiviral therapies for respiratory viral infections. The company’s activities center on research and development of drug candidates intended to treat or prevent illnesses such as influenza and COVID-19, with value creation primarily tied to advancing these candidates through clinical development and potential regulatory pathways.
TRAW Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced meaningful scientific and financing progress against important regulatory and liquidity risks. Positives include a $60M contingent financing package, robust preclinical data, a next-gen tablet with ~30% higher exposure supporting once-monthly prophylaxis, an approved Australian bridging study and plans for a U.K. human challenge trial. Key negatives are a low year-end cash balance ($3.8M), an FDA clinical hold on the IND for toxicology concerns that could materially delay U.S. development, and dependence on milestone warrants and one-time accounting items for near-term financial stability. Overall, the update conveys cautious optimism but highlights significant execution and regulatory risks that must be resolved to fully realize the program’s potential.View all TRAW earnings summariesTRAW Stock 12 Month Forecast
Average Price Target
$1.00
▲(104.08% Upside)
Technical Analysis
Ownership Overview
12.49% Insiders
0.74% Mutual Funds
20.83% Other Institutional Investors
63.77% Public Companies and
Individual Investors